Business Context and Reporting Period
This Form 8-K Current Report was filed by Protara Therapeutics, Inc. on July 18, 2022, covering events occurring on July 16, 2022. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of new financial leadership.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes and executive compensation arrangements.
Material Changes
- Departure of CFO: Blaine Davis, Chief Financial Officer, left the Company on July 15, 2022, to pursue other opportunities.
- Appointment of Controller: Effective July 16, 2022, Hannah Fry was appointed Controller and Principal Accounting Officer, reporting to the CEO.
- Appointment of PFO: Effective July 16, 2022, Jesse Shefferman, Chief Executive Officer, was appointed as the Principal Financial Officer.
Guidance, Outlook, and Compensation Details
The filing details the Executive Employment Agreement for Hannah Fry, effective July 16, 2022:
- Base Salary: $255,000 annually.
- Discretionary Bonus: Up to 35% of base salary.
- Equity Award: Subject to Board approval, an award of 25,000 restricted stock units (RSUs) vesting in full on the first anniversary of the grant date.
- Severance Provisions: In the event of termination without cause or resignation for good reason, Ms. Fry is entitled to six months of base salary, six months of healthcare premium reimbursement, and pro-rata vesting of outstanding equity awards (excluding the new RSU grant, which vests in full).
- Change in Control: If terminated for reasons other than cause, death, or disability within 18 months of a change in control, 100% of unvested equity awards accelerate.
The filing includes standard forward-looking statement disclaimers regarding Ms. Fry's continued employment and the nature of her role.
Investor Verification Checklist
- Verify the Board of Directors' approval of the 25,000 RSU grant to Hannah Fry, as the award is contingent upon such approval.
- Review the Company's proxy statement filed on April 27, 2022, for Jesse Shefferman's biography and compensation details.
- Monitor subsequent filings for the appointment of a permanent Chief Financial Officer, as the CEO is currently serving as Principal Financial Officer.
- Confirm the vesting schedule and grant date of the RSU award once approved by the Board.